








10 Products that Generated over \$100 Million US in 2006

	Drug name and company	Indications	FDA approval date	Quick facts
	1. Lyrica Pfizer Inc.	Diabetic peripheral neuropathy, pain after shingles and fibromyalgia	12/2004	Lyrica was 1 of 9 medicines with sales of more than \$1 billion US for Pfizer during 2006
	2. Lunesta Sepracor Inc.	Treatment of insomnia	12/2004	Lunesta was the most-advertised prescription drug to consumers last year at an expenditure of \$329 million US
	3. Byetta Amylin-Lilly	Improving blood-sugar control in adults with Type 2 diabetes	04/2005	Byetta franchise sales are expected, by industry analysts, to top \$2 billion US per year by 2011 after the launch of a long-acting formulation
	4. Boniva Hoffman LaRoche Inc.	Prevention and treatment of osteoporosis	05/2003	Boniva is approved for treating and preventing osteoporosis, which causes an estimated 1.5 million broken bones per year in America
	5. Menactra sanofi pasteur	Active immunization against invasive meningococcal disease	01/2005	Menactra and Adacel are marketed by sanofi pasteur, the largest company worldwide devoted entirely to human vaccines
	6. ProQuad Merck & Co	Vaccine for measles, mumps, rubella and chicken pox	09/2005	Merck & Co's ProQuad and Varivax are the only vaccines available in the US to help protect against chickenpox

Taken from MedAdNews, August 2007

10 Products that Generated over \$100 Million US in 2006

	Drug name and company	Indications	FDA approval date	Quick facts
	7. Adacel <i>Sanofi pasteur</i>	Vaccination against pertussis, tetanus and diphtheria	06/2005	Adacel is the first tetanus, diphtheria and acellular pertussis booster available for adolescents and adults 11 to 64-years-of-age
	8. Nexavar <i>Bayer HealthCare LLC</i>	Treatment of patients with advanced renal cell carcinoma	12/2005	Nexavar is Onyx Pharmaceuticals Inc.'s first commercially-available product and is being developed with Bayer HealthCare LLC
	9. Abraxane <i>AstraZeneca</i>	Treatment of metastatic breast cancer	01/2005	Abraxane almost doubles the response rate in metastatic breast cancer compared with Taxol, a former blockbuster brand
	10. Macugen <i>Pfizer Inc.</i>	Treatment of patients with wet age-related macular degeneration	12/2004	Macugen, formerly known as EYE001, was EYEtech Pharmaceutical Inc.'s lead product candidate after the company acquired the global rights for the anti-VEGF aptamer from Gilead Sciences Inc. in March 2000

Taken from MedAdNews, August 2007

CPM